Similar Papers

Paper Title
Journal
Date
Author
Metastatic Burden in Hormone-Naive Prostate Cancer: A Tale of Two Subgroups
Á.M Haran ... N.W Clarke
Clinical Oncology | VOL. 32
Á.M Haran, et. al.Á.M Haran ... N.W Clarke
25 Dec 2019
Metastatic prostate cancer management: 20 years of progress
Gwenaelle Gravis
The Lancet Oncology | VOL. 24
Gwenaelle GravisGwenaelle Gravis
01 May 2023
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Shivashankar Damodaran ... David F Jarrard
Journal of Urology | VOL. 201
Shivashankar Damodaran, et. al.Shivashankar Damodaran ... David F Jarrard
01 May 2019
The Case for Early Chemotherapy for the Treatment of Metastatic Disease
Aimee Lucas ... Daniel P Petrylak
The Journal of Urology | VOL. 176
Aimee Lucas, et. al.Aimee Lucas ... Daniel P Petrylak
01 Nov 2006
View more papers

More From: Future oncology (London, England)

Paper Title
Journal
Date
Author
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304).
Ciara Conduit ...
Future oncology (London, England) | VOL. -
Ciara Conduit, et. al.Ciara Conduit ...
17 Jan 2025
Real-world outcomes of first-line maintenance niraparib monotherapy in patients with epithelial ovarian cancer.
Ritu Salani ... Floor J Backes
Future oncology (London, England) | VOL. -
Ritu Salani, et. al.Ritu Salani ... Floor J Backes
17 Jan 2025
Open-label, phase Ia study of STING agonist BI 1703880 plus ezabenlimab for patients with advanced solid tumors.
Kevin Harrington ... Patricia Lorusso
Future oncology (London, England) | VOL. -
Kevin Harrington, et. al.Kevin Harrington ... Patricia Lorusso
16 Jan 2025
Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States.
Tammy A Schuler ... Bruce Feinberg
Future oncology (London, England) | VOL. -
Tammy A Schuler, et. al.Tammy A Schuler ... Bruce Feinberg
15 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.